160. 先天性魚鱗癬 Congenital ichthyosis Clinical trials / Disease details

臨床試験数 : 42 / 薬物数 : 71 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 112

diseases per page:

Showing 1 to 10 of 42 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05735158 (ClinicalTrials.gov)	March 2023	9/2/2023	Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)	A Phase 2, Randomized, Placebo-controlled Study of Topical KB105, a Replication-defective, Non-integ ...	Autosomal Recessive Ichthyosis	Biological: KB105;Other: Placebo	Krystal Biotech, Inc.	NULL	Not yet recruiting	6 Months	N/A	All	15	Phase 2	United States
2	NCT05443685 (ClinicalTrials.gov)	January 2, 2023	10/6/2022	ADX-629 Therapy for Sjogren-Larsson Syndrome	An Open-Label, Phase 1/2, Single-Site Study of the Safety, Biochemical Efficacy, and Exploratory Cli ...	Sjogren-Larsson Syndrome	Drug: ADX-629	William Rizzo, MD	NULL	Recruiting	18 Years	50 Years	All	10	Phase 1/Phase 2	United States
3	NCT05583669 (ClinicalTrials.gov)	November 8, 2022	13/10/2022	A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-232 ...	A Phase 1, Subject- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Seq ...	Netherton Syndrome	Drug: DS-2325a;Drug: Placebo	Daiichi Sankyo, Inc.	NULL	Recruiting	18 Years	50 Years	All	24	Phase 1	United States
4	NCT05388903 (ClinicalTrials.gov)	June 20, 2022	19/5/2022	A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous D ...	A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Se ...	Netherton Syndrome	Drug: DS-2325a;Drug: Placebo	Daiichi Sankyo, Inc.	NULL	Completed	18 Years	45 Years	All	64	Phase 1	United States
5	ChiCTR2200059272	2022-06-01	2022-04-27	A Basket Trial of the Safety and Efficacy of Ixekizumab in Participants with Autoimmune Inflammatory ...	A Basket Trial of the Safety and Efficacy of Ixekizumab in Participants with Autoimmune Inflammatory ...	pityriasis rubra pilaris, hidradenitis suppurativa, Netherton syndrome, erythrokeratodermia variabil ...	pityriasis rubra pilaris, Netherton syndrome, erythrokeratodermia variabilis and erythrokeratoderma ...	Dermatology Hospital of Southern Medical University	NULL	Pending			Both	pityriasis rubra pilaris, Netherton syndrome, erythrokeratodermia variabilis and erythrokeratoderma progressive symmetrica:30;hidradenitis suppurativa:10;	Phase 2	China
6	EUCTR2021-003210-39-AT (EUCTR)	01/02/2022	08/09/2021	A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled study to eval ...	A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-time-i ...	Netherton syndrome MedDRA version: 20.0;Level: PT;Classification code 10062909;Term: Netherton's syn ...	Product Code: SXR1096 INN or Proposed INN: SXR1096 Other descriptive name: SXR1096	Sixera Pharma	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 1;Phase 2	Finland;Austria
7	EUCTR2021-003210-39-FI (EUCTR)	23/11/2021	20/08/2021	A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled study to eval ...	A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-time-i ...	Netherton-syndrome MedDRA version: 20.0;Level: PT;Classification code 10062909;Term: Netherton's syn ...	Product Code: SXR1096	Sixera Pharma	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 1;Phase 2	Finland
8	NCT04996485 (ClinicalTrials.gov)	March 1, 2021	21/7/2021	Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for ...	Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for ...	Congenital Ichthyosis	Drug: Secukinumab Injection;Drug: Ustekinumab Injection;Drug: Dupilumab Injection;Other: Symptomatic th ...	National Medical Research Center for Children's Health, Russian Federation	NULL	Recruiting	6 Months	18 Years	All	50	Phase 4	Russian Federation
9	ChiCTR2000037278	2020-09-01	2020-08-27	Effects and Safety of Simvastatin Ointment in the Treatment of Congenital Ichthyosis	Effects and Safety of Simvastatin Ointment in the Treatment of Congenital Ichthyosis	inherited ichthyosis	ARCI group:Concentration of simvastatin cream;XLI group:Concentration of simvastatin cream;	Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	NULL	Recruiting			Both	ARCI group:45;XLI group:10;		China
10	NCT04244006 (ClinicalTrials.gov)	July 23, 2020	13/1/2020	A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Synd ...	A Randomized Double-blinded Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Pa ...	Netherton Syndrome	Drug: Dupilumab Prefilled Syringe;Other: Placebo Prefilled Syringe	University Hospital, Toulouse	MedSharing	Recruiting	18 Years	N/A	All	24	Phase 2/Phase 3	France

First Previous1 2 3 4 5Next Last